FDA approves Inspire therapy for pediatric Down syndrome patients with severe sleep apnea

The FDA approved Inspire therapy for pediatric patients with Down syndrome aged 13 and older with severe obstructive sleep apnea who are not effectively treated by tonsil and adenoid surgery and cannot tolerate positive airway pressure therapy.

Detected & updated continuously · Source: Nebula